Consistently with observations with the oral PDE4 inhibitor roflumilast in COPD, the chronic bronchitis phenotype was found to be a determinant of response in terms of exacerbation rate reduction (Singh et al., 2020c). Here, PDE4A is linked to chronic bronchitis.